News

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR-CM) is increasingly recognized in elderly patients with conduction disturbances and left ventricular…

Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for…

AbstractBackground: Cardiac transthyretin amyloidosis (ATTR-CM) is a progressive myocardial disease ultimately leading to heart failure. Standard diagnostic workup…

AbstractTransthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized because of improved diagnostic modalities and disease-modifying therapy. We report…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy caused by myocardial deposition of misfolded transthyretin, leading to…

Abstract and FiguresImportance Timely diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is critical for early treatment to reduce morbidity and mortality,…

Study OverviewBrief SummaryTransthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid…

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient…

Higher blood levels of fibroblast growth factor 23 (FGF23) — a bone-derived hormone — are associated with higher levels of established markers of heart damage and…

AbstractBackground: Advances in diagnostic criteria for transthyretin cardiac amyloidosis (ATTR-CM) and expanded insurance coverage for bone scintigraphy have…